Strona główna・Stock List・Vir Biotechnology Inc

Vir Biotechnology Inc

Open

SectorHealthcare

9.44 2.72

Buy Sell

Overview

Share price change

24h

Current

Min

9.11

Max

9.44

Key metrics
By Trading Economics
Income	80M -46M
Sales	239M 239M
EPS	0.47
Profit margin	-19.09
Employees	367
EBITDA	201M 78M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+130.41% upside

Dividends
By Acuity
Next Earnings	4 lis 2026

Market Stats
By TradingEconomics
Market Cap	3.3M 1.5B
Previous open	6.72
Previous close	9.44

News Sentiment

By Acuity

20%

80%

34 / 340 Ranking in Healthcare

Vir Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 sie 2026, 19:36 UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

10 sie 2026, 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

7 sie 2026, 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

6 sie 2026, 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

5 sie 2026, 23:41 UTC

News

Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

3 sie 2026, 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30 lip 2026, 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29 lip 2026, 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28 lip 2026, 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27 lip 2026, 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25 lip 2026, 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24 lip 2026, 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21 lip 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 lip 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Peer Comparison

Price change

Vir Biotechnology Inc Forecast

Price Target

By TipRanks

130.41% upside

12 Months Forecast

Average 21.29 USD 130.41%

High 30 USD

Low 15 USD

Based on 8 Wall Street analysts offering 12 month price targets forVir Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Vir Biotechnology Inc - Dist in the past 3 months.

Sentiment

By Acuity

34 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.